The Atlanta Journal-Constitution
3rd impurity found in blood-pressure drug
Drugmaker discovers potential carcinogen in its version of losartan.
India-based generic-drug company discovers potential carcinogen in its version of losartan.
A third potential cancer-causing contaminant has been found in a widely used blood-pressure medicine, according to the Food and Drug Administration.
India-based generic-drug company Hetero Labs Ltd. discovered a chemical called NMBA in its version of losartan, the FDA said in a statement Friday. The contamination was found during heightened testing stirred by a far-reaching recall of generic blood-pressure drugs known as angiotensin II receptor blockers, or ARBs, that contain potential carcinogens NDMA and NDEA.
A series of drugs have been identified as potentially dangerous since an initial recall began seven months ago. Hetero Labs’ losartan is repackaged and sold by closely held drugmaker Camber Pharmaceuticals Inc. in the U.S.
Camber said in a statement Thursday that it was recalling 87 lots of losartan tablets due to the discovery. The company said it hadn’t received any reports of patients being harmed related to the recall. Kirk Hessels, a spokesman for Camber, didn’t immediately respond to requests for comment Friday.
Problems with potential cancer-causing agents in blood-pressure medications first cropped up in July, when an ARB called valsartan was recalled by Chinese drugmaker Zhejiang Huahai Pharmaceutical Co.
The FDA has said it thinks the potential carcinogens, known as nitrosamine impurities, are a result of the manufacturing processes the companies used. The agency said the risk of a patient who took a recalled ARB getting cancer is low.
“That said, any presence of such impurities in drug products is not acceptable,” FDA Commissioner Scott Gottlieb said in the statement. “The FDA is committed to implementing measures to prevent the formation of these impurities during drug manufacturing processes in the future.”
‘Any presence of such impurities in drug products is not acceptable.’
Scott Gottlieb, FDA commissioner